Esperion Logo (primary).png
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
December 07, 2022 08:05 ET | Esperion Therapeutics, Inc.
– Demonstrates statistically significant and clinically meaningful results – – Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse...
Esperion Logo (primary).png
Esperion Appoints Ben Halladay Chief Financial Officer
November 16, 2022 16:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Ben Halladay, MBA, has been promoted to the role of Chief Financial Officer (CFO) from his prior...
Esperion Logo (primary).png
Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
November 09, 2022 08:00 ET | Esperion Therapeutics, Inc.
– Event to Include Expert-Led Discussions on State of Cardiovascular Disease Treatments and Remaining Unmet Needs – – Esperion Leadership Will Provide Overview of its Investigational Pipeline,...
Esperion Logo (primary).png
Esperion to Participate in Jefferies London Healthcare Conference
November 02, 2022 08:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and CEO, Sheldon Koenig, will present at the Jefferies London Healthcare Conference on...
Esperion Logo (primary).png
Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update
November 01, 2022 07:00 ET | Esperion Therapeutics, Inc.
– CLEAR Outcomes Trial Achieved Last Patient Last Visit in October Ensuring Timely Trial Completion – – Remain On Track to Report Topline Results in January 2023, with Full Results Targeted to be...
Esperion Logo (primary).png
Esperion Hosting Virtual Research & Development Day
October 27, 2022 08:00 ET | Esperion Therapeutics, Inc.
– Overview of its investigational pipeline, planned scientific focus, and future growth drivers – – Wednesday, November 9th @ 10amET – ANN ARBOR, Mich., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Esperion...
Esperion Logo (primary).png
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 19, 2022 16:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on October 18, 2022, the Compensation Committee of Esperion’s Board of Directors granted 5 new...
Esperion Logo (primary).png
Esperion to Participate in Upcoming September Investor Conferences
August 30, 2022 08:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and CEO, Sheldon Koenig, will present at Morgan Stanley’s 20th Annual Global Healthcare...
Esperion Logo (primary).png
Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway
August 26, 2022 08:16 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that bempedoic acid (NEXLETOL®) is now recommended as an important oral non-statin therapy for...
Esperion Logo (primary).png
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 04, 2022 16:05 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on August 2, 2022, the Compensation Committee of Esperion’s Board of Directors granted 13 new...